| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Biotin-PEG3-amine does not have a specific biological target, as it is a chemical probe. Its function is to enable the biotinylation of biomolecules for detection, purification, and signal amplification. The primary amine group is a target for conjugation with carboxylic acids or activated esters (e.g., NHS esters) to form stable amide bonds. The biotin moiety is a target for streptavidin or avidin, proteins that bind biotin with exceptionally high affinity (Kd ~10^-15 M). The hydrophilic PEG3 spacer enhances solubility and reduces steric hindrance between the biotin and the conjugated molecule. Therefore, Biotin-PEG3-amine acts as a versatile connector, enabling the precise labeling and capture of biomolecules.
|
|---|---|
| ln Vitro |
Biotin-PEG3-amine, as a probe, does not possess any direct in vitro biological activity, such as enzyme inhibition, receptor agonism, or cytotoxicity. Its function is to enable the biotinylation of biomolecules for detection, purification, and signal amplification. The in vitro activity of this probe is assessed indirectly through the characterization of the final biotinylated products it helps to create. For instance, when used to biotinylate a protein, the activity of the biotinylated protein is evaluated in assays for target binding, detection, or capture. The PEG3 linker contributes to the overall activity by enhancing solubility and reducing steric hindrance. Thus, the activity of Biotin-PEG3-amine is a measure of its utility as a synthetic building block.
|
| ln Vivo |
Biotin-PEG3-amine is not intended for in vivo use as a standalone compound. Its relevance in vivo is as a component of larger conjugates, such as biotinylated antibodies or drug delivery systems. In these contexts, the hydrophilic PEG3 spacer contributes to the overall pharmacokinetic profile of the conjugate by improving solubility and reducing aggregation. However, the specific in vivo activity—such as target binding or therapeutic efficacy—is determined by the conjugate's targeting ligand and payload, not the linker itself. The linker's role is to stably connect the functional components and enable detection or purification.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for Biotin-PEG3-amine, as it is not a biologically active compound. Its characterization is performed using analytical chemistry techniques such as NMR, HPLC, and MS to verify its structure and purity. The functionality of the primary amine group can be confirmed by reacting it with an NHS-ester-containing compound and monitoring the formation of the amide bond by HPLC or LC-MS. The functionality of the biotin moiety can be confirmed by a simple streptavidin binding assay, such as a dot blot or an ELISA. These are quality control and functional validation steps, not biological assays.
|
| Cell Assay |
There are no standard in vitro cell-based assays for Biotin-PEG3-amine itself, as it is not a bioactive molecule. Its use in cell biology is indirect, as a reagent for biotinylating biomolecules. For example, it can be used to create biotinylated antibodies or fluorescent probes for cellular imaging or pull-down experiments. In such cases, the cell-based assay would involve treating cells with the final conjugated probe and then measuring a biological readout, such as fluorescence intensity, protein localization, or the identification of binding partners. The performance of the linker would be evaluated by the efficiency and specificity of the bioconjugation and the functionality of the probe. However, there is no direct assay for the linker itself in cells.
|
| Animal Protocol |
Biotin-PEG3-amine is not used in in vivo animal experiments as a standalone compound. It is a synthetic building block for creating bioconjugates such as biotinylated antibodies or drug delivery systems. Animal studies would only be conducted on the final, larger conjugates that incorporate this linker. In such studies, the linker's contribution to the overall pharmacokinetic and pharmacodynamic profile of the conjugate might be assessed by comparing it to conjugates made with different linkers. However, there is no standard animal protocol for the linker itself. Its use is limited to the research and development phase, where it is employed in the chemical synthesis of test articles.
|
| ADME/Pharmacokinetics |
Biotin-PEG3-amine has a molecular weight of 418.55 g/mol and a molecular formula of C18H34N4O5S. Its IUPAC name is 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]pentanamide. It has a density of 1.2±0.1 g/cm³, a boiling point of 705.8±60.0 °C, and a logP of 1.34630. It is a white to almost white crystal powder with a purity of >98%. It is soluble in water. For storage, it is recommended to keep the powder at -20°C. Detailed pharmacokinetic properties are not relevant as the compound is a probe, not a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Biotin-PEG3-amine is considered to have low toxicity, consistent with other biotin and PEG-based reagents. Biotin is a vitamin and is generally recognized as safe (GRAS). PEG polymers are widely regarded as biocompatible, non-toxic, and non-immunogenic. The compound is classified as a research reagent, and standard laboratory safety precautions should be followed when handling it. Its toxicity profile has not been extensively studied, but due to its intended use and chemical class, it is not expected to be acutely toxic. All handling should be done with appropriate personal protective equipment (PPE) in a well-ventilated area, and the compound should be stored properly to prevent degradation.
|
| References | |
| Additional Infomation |
Biotin-PEG3-amine is a research-use-only reagent and is not a drug, nor is it approved for any clinical or therapeutic use. It is a heterobifunctional biotin derivative containing a biotin moiety and a terminal primary amine group, connected by a three-unit PEG spacer (PEG3). It is a signal amplification marker used in various biological and biochemical applications. The primary amine group enables conjugation to carboxylic acids, activated NHS esters, and other electrophilic groups. The biotin moiety provides high-affinity binding to streptavidin or avidin. The hydrophilic PEG3 spacer enhances water solubility and reduces steric hindrance. Biotin-PEG3-amine is a valuable tool for bioconjugation, enabling the creation of stable, well-defined conjugates for research applications.
|
| Molecular Formula |
C18H34N4O5S
|
|---|---|
| Molecular Weight |
418.5514
|
| Exact Mass |
418.225
|
| CAS # |
359860-27-8
|
| PubChem CID |
50896259
|
| Appearance |
White to off-white solid powder
|
| Density |
1.166±0.06 g/cm3
|
| Boiling Point |
705.8±60.0 °C
|
| Melting Point |
12°C
|
| Flash Point |
128°C(lit.)
|
| LogP |
1.346
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
28
|
| Complexity |
471
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCOCCOCCOCCN)NC(=O)N2
|
| InChi Key |
KIJSBKNJFAUJFV-ZOBUZTSGSA-N
|
| InChi Code |
InChI=1S/C18H34N4O5S/c19-5-7-25-9-11-27-12-10-26-8-6-20-16(23)4-2-1-3-15-17-14(13-28-15)21-18(24)22-17/h14-15,17H,1-13,19H2,(H,20,23)(H2,21,22,24)/t14-,15-,17-/m0/s1
|
| Chemical Name |
5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]pentanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~238.92 mM)
H2O : ~100 mg/mL (~238.92 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (119.46 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3892 mL | 11.9460 mL | 23.8920 mL | |
| 5 mM | 0.4778 mL | 2.3892 mL | 4.7784 mL | |
| 10 mM | 0.2389 mL | 1.1946 mL | 2.3892 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
